Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00394030 · ClinicalTrials.gov registry record · Phase 1
Injection Site Study In Patients With Type 2 Diabetes Mellitus (T2DM) And Healthy Volunteers
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
NCT00394030 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 63 participants.
The verdict
NCT00394030, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
Study Summary
This study is an open-label study in healthy volunteers and in patients with Type 2 Diabetes Mellitus to assess safety and tolerability parameters, the levels of GSK716155 in the bloodstream after a single dose given at different injection sites, and the impact this medication has on various substances in the blood. Assessments include ECGs, vital signs, repeat blood sampling and monitoring of any side effects.
Interventions
- DRUG GSK716155 subcutaneous injections
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2006-10-16 |
| Est. Completion | 2007-03-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00394030
The ClinicalTrials.gov registry entry for NCT00394030 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GSK716155 subcutaneous injections is the first listed.
NCT00394030 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00394030 about?
NCT00394030 is a clinical study titled "Injection Site Study In Patients With Type 2 Diabetes Mellitus (T2DM) And Healthy Volunteers". This study is an open-label study in healthy volunteers and in patients with Type 2 Diabetes Mellitus to assess safety and tolerability parameters, the levels of GSK716155 in the bloodstream after a single dose given at different injection sites, and the impact this medication has on various substan...
What is the current status of trial NCT00394030?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2006-10-16. Estimated completion is 2007-03-20.
What interventions are being tested in trial NCT00394030?
The interventions under investigation include: GSK716155 subcutaneous injections (DRUG).
Who is sponsoring clinical trial NCT00394030?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.